Reevaluating the role of interferon-beta in psoriasis pathogenesis: A registry-based self-controlled study.
immunomodulation
inflammatory diseases
interferon‐beta
psoriasis pathogenesis
skin
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
11 Jun 2024
11 Jun 2024
Historique:
revised:
24
05
2024
received:
02
05
2024
accepted:
31
05
2024
medline:
12
6
2024
pubmed:
12
6
2024
entrez:
12
6
2024
Statut:
aheadofprint
Résumé
Interferon-beta has been suggested as a trigger of psoriasis, yet a systematic investigation is lacking. This study aimed to assess the risk of developing psoriasis following interferon-beta treatment, utilizing a pharmaco-epidemiological approach to investigate the role of interferon-beta in psoriasis pathogenesis. We included all treatment-naïve patients with multiple sclerosis (MS) in Denmark who initiated interferon-beta treatment for MS from January 1996 to June 2023. These patients were compared to a control cohort of patients with MS treated with other disease-modifying drugs. We compared the incidence rates of psoriasis before and during the treatment. Data for this study were extracted from the Danish MS Registry and integrated with information from other national Danish health registries. Among 7174 patients treated with interferon-beta, the incidence rate of psoriasis post-treatment initiation was slightly higher (2.01 per 1000 person-years) compared to the rate prior to treatment (1.67 per 1000 person-years). This increase did not achieve statistical significance (P = 0.53), with an incidence rate ratio (IRR) of 1.20 (95% confidence interval [CI] 0.68-2.13). The control cohort showed an increase in psoriasis incidence post-treatment initiation (3.12 per 1000 person-years) compared to prior (1.11 per 1000 person-years), with an IRR of 2.80 (95% CI 1.36-4.77, P = 0.0038). This registry-based self-controlled study does not support the theory that interferon-beta acts as a trigger for psoriasis development.
Identifiants
pubmed: 38863198
doi: 10.1111/1346-8138.17338
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.
Références
Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. Int J Mol Sci. 2019;20:4347.
Gu H, Zhang Y, Zeng W, Xia Y. Participation of interferons in psoriatic inflammation. Cytokine Growth Factor Rev. 2022;64:12–20.
Amschler K, Meyersburg D, Kitze B, Schön MP, Mössner R. Onset of psoriasis upon interferon‐beta treatment in a multiple sclerosis patient. Eur J Dermatol. 2016;26:211–212.
La Mantia L, Capsoni F. Psoriasis during interferon‐beta treatment for multiple sclerosis. Neurol Sci. 2010;31:337–339.
Conrad C, Di Domizio J, Mylonas A, Belkhodja C, Demaria O, Navarini AA, et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun. 2018;9:25.
Yao Y, Richman L, Morehouse C, de los Reyes M, Higgs BW, Boutrin A, et al. Type I interferon: potential therapeutic target for psoriasis? PLoS One. 2008;3:e2737.
Paty DW, Li DK. Interferon‐beta‐1b is effective in relapsing‐remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double‐blind, placebo‐controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology. 1993;43:662–667.
Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology‐National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82:1445–1486.
Pottegård A, Schmidt SAJ, Wallach‐Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data resource profile: the Danish National Prescription Registry. Int J Epidemiol. 2017;46:798–798f.
Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–490.
Magyari M, Joensen H, Laursen B, Koch‐Henriksen N. The Danish Multiple Sclerosis Registry. Brain Behav. 2021;11:e01921.
Bissonnette R, Papp K, Maari C, Yao Y, Robbie G, White WI, et al. A randomized, double‐blind, placebo‐controlled, phase I study of MEDI‐545, an anti‐interferon‐alfa monoclonal antibody, in subjects with chronic psoriasis. J Am Acad Dermatol. 2010;62:427–436.
Harden JL, Johnson‐Huang LM, Chamian MF, Lee E, Pearce T, Leonardi CL, et al. Humanized anti‐IFN‐γ (HuZAF) in the treatment of psoriasis. J Allergy Clin Immunol. 2015;135:553–556.
Iskandar IYK, Parisi R, Griffiths CEM, Ashcroft DM, Global Psoriasis Atlas. Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender. Br J Dermatol. 2021;184:243–258.
Silfvast‐Kaiser AS, Homan KB, Mansouri B. A narrative review of psoriasis and multiple sclerosis: links and risks. Psoriasis. 2019;9:81–90.